The stakes are never higher than in the clinical phase of your drug development program – nearly 60% of drugs entering Phase III failing to achieve regulatory approval. By providing a longitudinal evaluation of disease-specific metabolic signatures during a trial, our Targeted Metabolomics Solution enhances monitoring of individual patient response to drug metabolism and toxicity, as well as provides improved post-approval drug monitoring.